Business Context and Reporting Period
Company: LecTec Corporation (Note: Request metadata listed "Axogen, Inc.", but the filing is for LecTec Corporation, which is pursuing a merger with AxoGen Corporation).
Reporting Period: Quarterly period ended June 30, 2011 (Form 10-Q).
Business Overview: LecTec is an intellectual property (IP) licensing and holding company. Its primary strategy is to pursue a merger to leverage its cash assets. The Company has entered into a definitive Merger Agreement with AxoGen Corporation, a developer of surgical products for peripheral nerve repair. LecTec's remaining operations include royalty income from a licensing agreement with Novartis Consumer Health, Inc. regarding adult vapor patches, and the development of a hand sanitizer patch prototype.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2011 | Six Months Ended June 30, 2010 |
|---|---|---|
| Total Revenue | $5,869,118 | $22,783 |
| Net Income (Loss) | $1,155,650 | $(476,316) |
| Operating Expenses | $3,870,881 | $736,352 |
| Cash and Cash Equivalents (End of Period) | $7,840,329 | $9,634,083 |
| Total Assets | $12,160,567 | $10,143,477 |
| Working Capital | $8,981,367 | $9,972,819 |
| Current Ratio | 15.69 | 88.21 |
Debt and Liquidity: The Company has no long-term debt. It holds significant cash reserves and certificates of deposit. However, it has extended $2.5 million in loans to AxoGen Corporation (secured by AxoGen assets) in anticipation of the merger.
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased from $22,783 in the prior year period to $5.87 million. This is primarily due to non-recurring items:
- Patent Infringement Settlements: $3.825 million recognized (including $3.6 million from Chattem Inc. and $225,000 from Prince of Peace Enterprises).
- IP Sale: $2.0 million from the sale of hydrogel patch patents to Endo Pharmaceuticals Inc.
- Royalties: Recurring royalty income from Novartis increased to $44,118 (from $22,783) due to seasonal demand.
- Operating Expenses: Expenses rose significantly to $3.87 million (from $736,352). This increase is driven by:
- ~$2.45 million in litigation contingency fees and expenses.
- ~$435,000 in merger and IP sale related expenses.
- ~$338,000 in non-cash stock-based compensation.
- Profitability: The Company turned a net loss of $(476,316) in the prior year into a net income of $1.16 million, driven by the one-time settlement and asset sale proceeds.
Guidance, Outlook, and Risks
Merger with AxoGen: The Company is focused on closing the merger with AxoGen Corporation. Upon closing, AxoGen stockholders are expected to own approximately 60% of the combined company. The transaction is subject to shareholder approval and a condition that LecTec maintains a "Net Cash" position of at least $10.5 million at closing.
Outlook: Management intends to fund operations via royalty income and asset sales while reducing costs. Future royalty income from Novartis is estimated at $50,000 to $75,000 annually but is subject to market volatility.
Risks and Contingencies:
- Merger Failure: If the merger does not close, the Company may face liquidity issues if it must repay the $2.5 million loan to AxoGen or if AxoGen cannot secure alternative financing for its own debt due in September 2011.
- Integration Risks: Post-merger integration challenges and the transition of AxoGen to a public company structure.
- Stock Volatility: The issuance of new shares to AxoGen stockholders will dilute existing LecTec shareholders to approximately 40% ownership.
- IP Expiration: Remaining hydrogel IP has limited value due to approaching patent expirations.
Investor Verification Checklist
- Merger Approval: Verify the status of shareholder votes for both LecTec and AxoGen required to consummate the merger.
- Net Cash Condition: Confirm that LecTec's cash position (including the $2.5M loan to AxoGen) meets the $10.5 million threshold required for the merger closing.
- AxoGen Financing: Monitor whether AxoGen secures its new $5.0 million loan facility to refinance its existing debt due September 30, 2011.
- One-Time vs. Recurring Income: Distinguish between the $5.8 million revenue (mostly one-time settlements/sales) and the recurring royalty stream (~$50k-$75k/year) when valuing the company.
- Dilution Impact: Assess the impact of the issuance of ~6.1 million new shares to AxoGen stockholders on the market price and voting power of existing LecTec shareholders.